Company intelligence / Profile preview

Galileo Research

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Galileo Research is a non-clinical CRO with over 30 years of experience in GLP-compliant studies. It provides toxicology, biocompatibility, efficacy/performance, and mechanism-of-action studies for drugs, medical devices, food supplements, and cosmetics to support regulatory submissions. The company does not have its own clinical pipeline but has contributed to the development of bisphosphonates such as clodronate and alendronate through its historical roots.

Therapeutic areas: OncologyRheumatologyNeurology
Modalities: Small moleculeBiologicAdvanced therapy (including cell and gene therapies)Medical device testing
Industry: Drug Discovery Services

Partnerships

No major pharmaceutical or biotech partnerships publicly listed; historically linked to Abiogen Pharma.

Beyond the preview

Go deeper on Galileo Research.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Galileo Research.

Explore the full profile